Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

Figure 1

The addition of IL-7 sensitized the A549/DDP cells to DDP-induced tumor inhibition. (a) A series of DDP (0–50 μg/mL) doses was added to the human lung cancer cell line A549 and DDP-resistant cell line A549/DDP. The cell vitality was estimated by CCK-8 assay and the IC₅₀ value (half-maximal (50%) inhibitory concentration) was calculated. (b) A549/DDP cell lines were treated with IL-7 (2 ng/mL) and/or DDP (0.5 μg/mL) for 24 h, 48 h, and 72 h; the cell vitalities were analyzed by CCK-8 assay. (c, d) EdU staining was performed 48 h after the indicated treatment to estimate the proliferation of the A549/DDP cell line. (e, f) Colony formation assay and the quantified number of colonies of A549/DDP cells after the indicated treatment. , , and , as compared with the control group; and , as compared with the DDP group. Data are presented in terms of .

(a)

(b)

(c)

(d)

(e)

(f)